These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 28271030)

  • 1. High-fidelity
    Ackermann AM; Zhang J; Heller A; Briker A; Kaestner KH
    Mol Metab; 2017 Mar; 6(3):236-244. PubMed ID: 28271030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gcg
    Shiota C; Prasadan K; Guo P; Fusco J; Xiao X; Gittes GK
    Diabetologia; 2017 Dec; 60(12):2399-2408. PubMed ID: 28884202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted knock-in of CreER
    Kesavan G; Hammer J; Hans S; Brand M
    Cell Tissue Res; 2018 Apr; 372(1):41-50. PubMed ID: 29435650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncovering the role of MAFB in glucagon production and secretion in pancreatic α-cells using a new α-cell-specific Mafb conditional knockout mouse model.
    Chang YH; Katoh MC; Abdellatif AM; Xiafukaiti G; Elzeftawy A; Ojima M; Mizuno S; Kuno A; Takahashi S
    Exp Anim; 2020 Apr; 69(2):178-188. PubMed ID: 31787710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporally controlled somatic mutagenesis in smooth muscle.
    Kühbandner S; Brummer S; Metzger D; Chambon P; Hofmann F; Feil R
    Genesis; 2000 Sep; 28(1):15-22. PubMed ID: 11020712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cre-driver rat model for anatomical and functional analysis of glucagon (Gcg)-expressing cells in the brain and periphery.
    Zheng H; López-Ferreras L; Krieger JP; Fasul S; Cea Salazar V; Valderrama Pena N; Skibicka KP; Rinaman L
    Mol Metab; 2022 Dec; 66():101631. PubMed ID: 36368622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2.
    Higashi AY; Ikawa T; Muramatsu M; Economides AN; Niwa A; Okuda T; Murphy AJ; Rojas J; Heike T; Nakahata T; Kawamoto H; Kita T; Yanagita M
    J Immunol; 2009 May; 182(9):5633-40. PubMed ID: 19380810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells.
    Hayashi Y; Yamamoto M; Mizoguchi H; Watanabe C; Ito R; Yamamoto S; Sun XY; Murata Y
    Mol Endocrinol; 2009 Dec; 23(12):1990-9. PubMed ID: 19819987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of tamoxifen-inducible CRE recombinase in Lcn5-CreER
    Xu J; Yao G; Ru Y; Xie S
    Mol Reprod Dev; 2017 Mar; 84(3):257-264. PubMed ID: 28029195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-mediated targeting of the Rosa26 locus produces Cre reporter rat strains for monitoring Cre-loxP-mediated lineage tracing.
    Ma Y; Yu L; Pan S; Gao S; Chen W; Zhang X; Dong W; Li J; Zhou R; Huang L; Han Y; Bai L; Zhang L; Zhang L
    FEBS J; 2017 Oct; 284(19):3262-3277. PubMed ID: 28763160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly B lymphocyte-specific tamoxifen inducible transgene expression of CreER T2 by using the LC-1 locus BAC vector.
    Boross P; Breukel C; van Loo PF; van der Kaa J; Claassens JW; Bujard H; Schönig K; Verbeek JS
    Genesis; 2009 Nov; 47(11):729-35. PubMed ID: 19621440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of tamoxifen-inducible Pax9-CreER knock-in mice using CrispR/Cas9.
    Feng J; Jing J; Sanchez-Lara PA; Bootwalla MS; Buckley J; Wu N; Yan Y; Chai Y
    Genesis; 2016 Sep; 54(9):490-6. PubMed ID: 27381449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the
    Lesaffer B; Verboven E; Van Huffel L; Moya IM; van Grunsven LA; Leclercq IA; Lemaigre FP; Halder G
    Cells; 2019 Apr; 8(4):. PubMed ID: 31027317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The generation and characterization of novel Col1a1FRT-Cre-ER-T2-FRT and Col1a1FRT-STOP-FRT-Cre-ER-T2 mice for sequential mutagenesis.
    Zhang M; Kirsch DG
    Dis Model Mech; 2015 Sep; 8(9):1155-66. PubMed ID: 26183214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic activation of α-cell glucokinase in mice causes enhanced glucose-suppression of glucagon secretion during normal and diabetic states.
    Bahl V; Lee May C; Perez A; Glaser B; Kaestner KH
    Mol Metab; 2021 Jul; 49():101193. PubMed ID: 33610858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mouse model with tamoxifen-inducible thyrocyte-specific cre recombinase activity.
    Undeutsch H; Löf C; Offermanns S; Kero J
    Genesis; 2014 Apr; 52(4):333-40. PubMed ID: 24395757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vegfr3-CreER (T2) mouse, a new genetic tool for targeting the lymphatic system.
    Martinez-Corral I; Stanczuk L; Frye M; Ulvmar MH; Diéguez-Hurtado R; Olmeda D; Makinen T; Ortega S
    Angiogenesis; 2016 Jul; 19(3):433-45. PubMed ID: 26993803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactate activation of α-cell K
    Zaborska KE; Dadi PK; Dickerson MT; Nakhe AY; Thorson AS; Schaub CM; Graff SM; Stanley JE; Kondapavuluru RS; Denton JS; Jacobson DA
    Mol Metab; 2020 Dec; 42():101056. PubMed ID: 32736089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion.
    da Silva Xavier G; Farhan H; Kim H; Caxaria S; Johnson P; Hughes S; Bugliani M; Marselli L; Marchetti P; Birzele F; Sun G; Scharfmann R; Rutter J; Siniakowicz K; Weir G; Parker H; Reimann F; Gribble FM; Rutter GA
    Diabetologia; 2011 Apr; 54(4):819-27. PubMed ID: 21181396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Nkx2-5/CreER transgenic mice for inducible Cre expression in developing hearts.
    Ranjbarvaziri S; Park S; Nguyen NB; Gilmore WB; Zhao P; Ardehali R
    Genesis; 2017 Aug; 55(8):. PubMed ID: 28589709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.